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Recipient Outcomes From Nondirected Live
Kidney Donors: A UK-based Cohort Study
Jay Nath, PhD,1 Kamlesh Patel, MBChB,1,2 Melanie Field, MD,1 James Hodson, BSc,3 Adnan Sharif, MD,4
Nicholas G. Inston, PhD,1 and Andrew R. Ready, MD1
Background. Increasing numbers of patients with end-stage renal failure are receiving kidneys from nondirected kidney donors
(NKDs), also known as altruistic donors. Transplant outcomes for recipients of such kidneys are largely inferred from studies on
specified kidney donors (SKDs), which may be inaccurate due to differences in donor, recipient and transplant specific factors.
We report the outcomes for recipients of NKD in the United Kingdom.Methods.Outcomes for 6861 patients receiving a living
donor kidney transplant between January 2007 and December 2014 were analyzed using both the National Health Service Blood
and Transplant and the UK Renal Registry datasets. Graft and patient outcomes were compared for patients receiving NKD and
SKD organs using univariable and multivariable analyses. Results. There was significant discordance between the NKD and SKD
donors and recipients. These included increased donor age (median, 58 years vs 47 years; P < 0.001) and higher rates of hemodi-
alysis and previous transplants in the NKD group (both P < 0.001). Despite such markers of increased risk among both donors and
recipients of NKD kidneys, there was no difference in graft survival on univariable (hazard ratio, 1.20; 95% confidence interval,
0.77-1.86; P = 0.419) or multivariable analysis (hazard ratio, 1.13; 95% confidence interval, 0.65-1.95; P = 0.665).Conclusions.
Despite some markers of transplant complexity, nondirected kidney donor organs are an excellent source of organs for
transplantation.
(Transplantation Direct 2018;4: e406; doi: 10.1097/TXD.0000000000000847. Published online 15 November, 2018.)
The Human Tissue Act 2004
1 included regulatory over-
sight for living kidney donation, and thus, nondirected
kidney donation was allowed for the first time when it came into
force. Nondirected kidney donor (NKD) organs, also known as
altruistic, good Samaritan, anonymous, or unspecified, donor
kidneys, are donated to a nondirected recipient without an
emotional link.2 The number of nondirected kidney donors
has increased dramatically following this, with a near fourfold
increase in the United Kingdom between 2010 and 2014
(Figure 1), similar to trends observed in the United States.3
Nondirected kidney donor organs are now an important
source of donor kidneys and recent data demonstrate they
now constitute over 6% all live donor transplants performed
in the United Kingdom4 and 3% in the United States.3
Allocation of NKD organs has been a source of debate for
both ethicists and clinicians alike. Although practices vary be-
tween institutions, these organs are normally either allocated
to patients on the nationwide deceased-donor waiting list or
used to trigger a transplantation chain. Although various
models have been proposed to optimize such chain usage,5-9
the net result is that availability of a single NKD organ facili-
tates 2 or more transplants.10,11
A recent study of donors of NKD organs found that they
were older, with a greater proportion of retirees, compared
with specified kidney donor (SKD) counterparts.12 This
may have negative consequences, given the correlation be-
tween increasing donor age and less favorable transplant out-
comes.13-15 In addition to donor differences, recipients of
NKD organs also differ from the SKD cohort. The majority
of NKD organs are allocated to the deceased-donor waiting
list, where recipients are generally more medically complex
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than the standard live donor recipient.16 Although the prog-
nostic significance of closeHLA compatibility is less important
for graft longevity than it once was, SKD kidney are often
from genetically related individuals (eg, siblings / parents)
which are known to have a greater degree of genetic match,
compared to genetically unrelated kidneys.17 Finally, the do-
nor nephrectomy and organ implant for NKD operations are
often performed at the transplant centers closest to each
donor/recipient, resulting in split-site procedures involving
2 separate medical teams, organ transport, and a resultant
increase in cold ischemic time (CIT).
Yet despite the differences between SKD and NKD trans-
plants and the increasing importance of NKD transplants,
the outcomes for the recipients of these kidneys have not been
assessed in a large data set, although reports from small series
are encouraging.18-22 We hypothesize that NKD transplants
have excellent outcomes despite the differences in donor-,
recipient-, and transplant-specific factors and aim to test this
hypothesis using the United Kingdom national data set.
MATERIALS AND METHODS
Study Design
Retrospective cohort registry study of patients receiving a
living donor kidney transplant. The association between do-
nor type (NKD vs SKD) and outcome was assessed. Primary
outcome measures were allograft survival (death censored)
and patient survival. Secondary outcome measures included
creatinine values (at 1 year) and delayed graft function
(DGF), defined as the need for dialysis in the first week after
transplantation.
Study Population
Adult patients (older than 18 years) receiving a single or-
gan living donor kidney transplant between January 2007
and December 2014 in the United Kingdom were included.
Kidney transplant centers within the United Kingdom are
obliged to submit demographic and clinical data to both
NHS Blood and Transplant (NHSBT) and Renal Registry
professional bodies for each transplant performed. The
2 bodies collect different patient specific and outcome vari-
ables and therefore amalgamation of the 2 data sets was per-
formed in an attempt to maximize the variables included.
This study was approved by the 2 database review boards
above, but did not require separate ethical board approval,
due to the nature of the study performed.
Statistical Methods
Initially, a range of factors were compared between the
SKD and NKD cohorts. Categorical variables were analyzed
using χ2 tests. Continuous variables were assessed for nor-
mality before the analysis, with independent samples t tests
used where this assumption was met, and Mann-Whitney
tests used for nonnormal or ordinal data.
Survival outcomes in the 2 groups were assessed using
Kaplan-Meier curves, with hazard ratios (HRs) and P values
from univariable Cox regression models. These were followed
by multivariable Cox regression analyses, in order to compare
the outcomes of the 2 groups, after accounting for potentially
confounding factors. The donor type was entered into the
model, alongside all of the potentially confounding factors
for which data were available. Continuous variables were
converted into ordinal categories, to improve model fit, with
ethnicity and graft number dichotomized, to give sufficient
within-category sample sizes to produce reliable HRs. Be-
cause of the amount of missing data for the wait time and
sensitization, a sensitivity analysis was performed by generat-
ing separate models with and without considering these
factors. These gave consistent results; hence, the latter is
quoted throughout to maximize the sample sizes considered.
A similar approachwas employed for the analysis of 1 year
creatinine and DGF. The former was log10-transformed, be-
fore analysis, in order to normalize the distribution, before
being compared between the groups using an independent
samples t test andmultivariable general linear model. The co-
efficients from the multivariable model were then antilogged,
and converted into percentage differences between groups for
ease of interpretation. Rates of DGFwere compared between
the groups using a χ2 test, with multivariable analysis by bi-
nary logistic regression.
All analyses were performed using IBM SPSS 22 (IBM
Corp. Armonk, NY). Cases with missing data were excluded
on a per-analysis basis, and P less than 0.05 was deemed to
be indicative of statistical significance throughout.
RESULTS
Patient Demographics
Data were available for 6861 transplants between January
2007 and December 2014, of which 358 (5.2%) were from
nondirected donors. The number of NKDs increased sig-
nificantly over the period of the study (Kendall's Tau:
P < 0.001, Figure 1). The first recorded NKD transplants
(n = 3) occurred in 2007, accounting for less than 0.5% of
the total living transplants that year, increasing to 12%of liv-
ing transplants by 2014 (n = 108).
Comparisons of donor and recipient factors in NKD and
SKD groups are reported in Table 1A. Nondirected donors
were found to be significantly older (P < 0.001), more likely
to be male (P = 0.010) and of white ethnicity (P < 0.001)
and to have significantly lower BMI (P < 0.001) than speci-
fied donors.
There were also differences between the recipients of NKD
organs compared to SKD counterparts. Recipients of NKD
organs were significantly older, and less likely to be male
and of white ethnicity (all P < 0.001). The NKD recipients
FIGURE 1. Numbers of nondirected kidney donors per year.
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were also significantlymore likely to have previously received
a renal transplant, with higher rates of pretransplant hemodi-
alysis and lower rates of preemptive transplantation also
noted (all P < 0.001).
Of the matching and surgical factors considered (Table 1B),
NKD organs had multiple markers of transplant complexity
with significantly longer CIT, waiting list duration, and de-
gree of sensitization (all P < 0.001). There were fewer HLA
mismatches in the NKD group compared with SKD organs
(P < 0.001).
Univariable Analyses of Survival Outcomes
Outcome measures for SKD and NKD groups were com-
pared using univariable analyses (Table 2). These found no
significant difference in rates of allograft survival (death
censored) between the NKD and SKD groups (HR, 1.20;
95% confidence interval [CI], 0.77-1.86; P = 0.419; Figure 2a.
However, patient survival was inferior in the NKD group,
relative to SKD, with 1- and 3-year survival rates of 96.9%
versus 98.9% and 92.8% versus 97.2%, respectively (HR,
2.60; 95% CI, 1.66-4.07; P < 0.001; Figure 2B).
Multivariable Analysis of Survival Outcomes
Multivariable Cox regression models were then produced
to account for the effects of potentially confounding factors
(Table 3). Patient survival was found to be significantly
shorter in older recipients, those with diabetes or CMV, and
patients on hemodialysis at the time of transplant. In addi-
tion, recipients of organs from older donors and those with
HLA incompatibility also had significantly shorter survival.
After accounting for these factors, no significant difference
in patient survival between NKD and SKD organs was de-
tected (HR, 1.68; 95% CI, 0.90-3.16; P = 0.104).
Multivariable analysis of death-censored allograft survival
also found hemodialysis at transplant, increasing donor age
and HLA incompatibility to be significantly predictive of
poorer prognosis. In addition, younger recipients, and those
who had received previous transplants also had significantly
shorter death-censored allograft survival. After accounting for
these factors, no significant difference between NKD and SKD
organs was detected (HR, 1.13; 95%CI, 0.65-1.95; P = 0.665).
Other Outcomes
Creatinine levels at 1 year were available in 5259 patients.
Geometric mean levels were similar in the 2 patient groups
TABLE 1A.
Association between kidney type and patient demographics
Valid, n
Donor type
PSpecified Nondirected
Donor factors
Age (median + IQR) 6861 47 (39-56) 58 (48-65) <0.001
Sex (male) 6860 2978 (45.8%) 189 (52.8%) 0.010
BMI, mean (SD)a 6541 26.6 ± 4.0 25.4 ± 3.3 <0.001
Ethnicity 6855 <0.001
White 5581 (85.9%) 352 (98.3%)
Asian 525 (8.1%) 5 (1.4%)
Black 269 (4.1%) 1 (0.3%)
Other 122 (1.9%) 0 (0.0%)
Blood group 6846 <0.001
A 1968 (30.3%) 183 (51.1%)
B 480 (7.4%) 32 (8.9%)
O 4040 (62.3%) 143 (39.9%)
Recipient factors
Age (median + IQR) 6861 45 (34-56) 49 (41-59) <0.001
Sex (male) 6853 3925 (60.4%) 189 (52.8%) 0.005
Ethnicity 6781 <0.001
White 5476 (85.2%) 278 (78.1%)
Asian 555 (8.6%) 51 (14.3%)
Black 282 (4.4%) 23 (6.5%)
Other 112 (1.7%) 4 (1.1%)
Diabetes 6861 389 (6.0%) 26 (7.3%) 0.306
Dialysis at transplant 6296 <0.001
Hemodialysis 2940 (49.3%) 235 (71.2%)
Peritoneal dialysis 1183 (19.8%) 74 (22.4%)
Not on dialysis 1843 (30.9%) 21 (6.4%)
Graft number 6861 <0.001
1 5639 (86.7%) 271 (75.7%)
2 723 (11.1%) 68 (19.0%)
3+ 141 (2.2%) 19 (5.3%)
CMV positive 6491 2851 (46.3%) 180 (53.4%) 0.012
Blood group 6861 <0.001
A 2836 (43.6%) 163 (45.5%)
AB 213 (3.3%) 25 (7.0%)
B 765 (11.8%) 46 (12.8%)
O 2689 (41.4%) 124 (34.6%)
P values from Mann-Whitney for continuous variables, and χ2 tests for categorical variables, unless
stated otherwise.
a P value from independent samples t test.
IQR, interquartile range.
TABLE 1B.
Association between kidney type and
matching/transplant factors
Valid, n
Donor type
PSpecified Nondirected
CIT: median (IQR), min 6239 180 (120-231) 330 (242-408) <0.001
Wait time: median (IQR) 5036 261 (105-562) 1141 (597-1730) <0.001
Sensitization 4721 <0.001
0 2578 (59.1%) 173 (48.5%)
1-20 255 (5.8%) 23 (6.4%)
21-80 932 (21.4%) 85 (23.8%)
81-100 599 (13.7%) 76 (21.3%)
Year of transplant 6861 <0.001
2007-2008 1530 (23.5%) 15 (4.2%)
2009-2010 1676 (25.8%) 40 (11.2%)
2011-2012 1641 (25.2%) 89 (24.9%)
2013-2014 1656 (25.5%) 214 (59.8%)
HLA mismatch group 6844 <0.001
1 669 (10.3%) 74 (20.7%)
2 855 (13.2%) 138 (38.5%)
3 3005 (46.3%) 121 (33.8%)
4 1957 (30.2%) 25 (7.0%)
AITX typea 6861 0.350
Not present 6123 (94.2%) 342 (95.5%)
HLAi 380 (5.8%) 16 (4.5%)
P values from Mann-Whitney tests on noncategorized data, unless stated otherwise.
a P value from χ2 test.
HLAi, incompatible.
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(P = 0.885), at 120.1 μmol/L versus 120.4 μmol/L in trans-
plants from SKD versus NKD (Table 4). This difference
remained nonsignificant after accounting for potentially con-
founding factors on multivariable analysis (P = 0.294).
The DGF rates were found to be significantly higher in
nondirected donors in univariable analysis (6.3% vs 3.9%;
P = 0.037). After accounting for potentially confounding fac-
tors in a multivariable analysis, this difference became non-
significant (P = 0.370), with an odds ratio of 0.92 (95%
CI, 0.50-1.67; P = 0.777) for nondirected versus specified
donor kidneys.
DISCUSSION
This is the largest published study to report recipient out-
comes for NKD organs, using a national data set with a high
proportion of such donors. We found, as anticipated, that
NKD kidney have excellent outcomes and, after adjusting
for significant confounding donor and recipient factors, these
were comparable to SKD organs.
This study serves to highlight that there are a multitude
of differences between the NKD and SKD transplants with
regard to donor-, recipient-, and transplant-specific factors,
which must be considered when counseling a potential
NKD recipient. First, donors of NKD organs are on average
more than a decade older than SKD counterparts, with 40%
of NKD donors older than 60 years. Such age equivalent kid-
neys are classified as extended criteria in the cadaveric setting,
with associated inferior outcomes (other qualifiers are donor
aged 50 to 59 yearswith at least 2 of the other 3 conditions (ce-
rebrovascular cause of death, renal insufficiency [serum creat-
inine, >132 μmol/L], and hypertension).23,24 Second, there are
inherent differences in recipients of NKD kidneys, compared
with SKD counterparts, with higher levels of sensitization, lon-
ger waiting list times and a higher proportion on hemodialysis
before transplantation (Table 1B). Thirdly, NKDorgans trans-
planted in the United Kingdom are normally performed across
different donor and recipient sites. This adds a degree of logis-
tical complexity to NKD transplantation, and inevitably, the
CIT is prolonged. Interestingly, the degree of HLA mismatch
is actually greater for SKD organs, which is perhaps surprising
given that NKDorgans are always from unrelated individuals.
However, this is likely to reflect the priority given to matching
recipients of such organs for patients on the cadaveric kidney
waiting list.
However, despite these markers of transplant complexity
associated withNKD organs in the United Kingdom, the out-
comes for such kidneys are excellent. Indeed, even before
adjustment for these confounding factors, there was no sig-
nificant difference in graft survival or 1 year creatinine values
between NKD and SKD kidneys. We hope these results
TABLE 2.
Summary of graft survival analyses
Kaplan-Meier estimated survival at:
Cox regression analysis
Univariable Multivariablea
Outcome 1 y 2 y 3 y HR (95% CI) P HR (95% CI) P
Patient survival
Specified 98.9% 98.1% 97.2% — — — —
Nondirected 96.9% 95.5% 92.8% 2.60 (1.66-4.07) <0.001 1.68 (0.90-3.16) 0.104
Allograft survival (death censored)
Specified 97.0% 95.7% 94.2% — — — —
Nondirected 95.4% 93.6% 92.8% 1.20 (0.77-1.86) 0.419 1.13 (0.65-1.95) 0.665
Univariable survival analyses are based on the 6813 patients with survival data reported.
a Full models are reported in Table 3.
FIGURE 2. A, Kaplan-Meier curve of death-censored allograft sur-
vival. B, Kaplan-Meier curve of patient survival.
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TABLE 3.
Multivariable analysis of survival outcomes
Patient survival Allograft survival (death-censored)
HR (95% CI) P HR (95% CI) P
Donor type (nondirected) 1.68 (0.90-3.16) 0.104 1.13 (0.65-1.95) 0.665
Recipient age, y <0.001 <0.001
< 40 — — — —
40-49 2.08 (1.22-3.53) 0.007 0.65 (0.49-0.85) 0.002
50-59 3.24 (1.92-5.48) <0.001 0.54 (0.39-0.74) <0.001
60+ 7.71 (4.70-12.62) <0.001 0.62 (0.44-0.87) 0.006
Recipient sex (Male) 1.08 (0.80-1.47) 0.599 0.86 (0.70-1.07) 0.178
Recipient ethnicity (nonwhite) 0.56 (0.25-1.23) 0.148 1.02 (0.60-1.74) 0.930
Recipient diabetes (yes) 2.43 (1.62-3.66) <0.001 0.83 (0.50-1.38) 0.473
Dialysis at transplant <0.001 0.010
Hemodialysis — — — —
Peritoneal dialysis 0.55 (0.36-0.82) 0.003 0.81 (0.62-1.07) 0.139
Not on dialysis 0.53 (0.37-0.76) 0.001 0.66 (0.50-0.87) 0.003
Previous grafts (yes) 1.37 (0.88-2.15) 0.164 1.57 (1.18-2.10) 0.002
Recipient CMV (positive) 1.37 (1.03-1.84) 0.033 0.99 (0.80-1.23) 0.926
Recipient blood group 0.371 0.691
A — — — —
AB 0.30 (0.07-1.25) 0.097 0.73 (0.38-1.42) 0.352
B 0.76 (0.36-1.62) 0.478 0.89 (0.51-1.55) 0.687
O 1.01 (0.67-1.53) 0.967 1.08 (0.79-1.49) 0.618
Donor age, y 0.002 0.016
< 40 — — — —
40-49 1.95 (1.26-3.02) 0.003 1.40 (1.05-1.86) 0.021
50-59 1.24 (0.76-2.01) 0.383 1.07 (0.79-1.46) 0.662
60+ 2.08 (1.31-3.33) 0.002 1.55 (1.12-2.17) 0.009
Donor sex (male) 0.90 (0.67-1.21) 0.495 0.89 (0.72-1.10) 0.285
Donor BMI 0.776 0.317
25 — — — —
25-29 1.13 (0.82-1.55) 0.464 1.13 (0.89-1.44) 0.322
30-34 1.14 (0.76-1.71) 0.539 1.32 (0.98-1.77) 0.069
35+ 0.67 (0.16-2.74) 0.574 1.32 (0.66-2.62) 0.434
Donor ethnicity (nonwhite) 2.05 (0.91-4.63) 0.082 1.52 (0.88-2.64) 0.137
Donor blood group 0.809 0.604
A — — — —
B 1.08 (0.41-2.86) 0.875 0.82 (0.42-1.60) 0.565
O 0.90 (0.59-1.37) 0.608 0.85 (0.61-1.18) 0.324
Transplant year 0.514 0.127
2007-2008 — — — —
2009-2010 1.01 (0.71-1.42) 0.964 0.76 (0.58-0.99) 0.042
2011-2012 0.76 (0.48-1.20) 0.236 0.73 (0.54-1.01) 0.054
2013-2014 0.72 (0.37-1.39) 0.332 0.80 (0.54-1.19) 0.278
HLA mismatch group 0.894 0.175
1 — — — —
2 0.96 (0.54-1.71) 0.890 1.32 (0.84-2.07) 0.227
3 0.86 (0.52-1.42) 0.552 1.50 (1.01-2.23) 0.044
4 0.95 (0.56-1.59) 0.835 1.26 (0.82-1.94) 0.283
AITX type (HLAi) 2.08 (1.28-3.39) 0.003 1.72 (1.21-2.44) 0.002
CIT, min 0.378 0.156
< 120 — — — —
120-179 1.04 (0.68-1.57) 0.868 1.26 (0.93-1.69) 0.132
180-239 1.31 (0.89-1.93) 0.165 1.11 (0.83-1.49) 0.493
240+ 1.33 (0.87-2.04) 0.192 1.41 (1.02-1.93) 0.035
Results are from multivariable Cox regression models, based on N = 5213, after excluding cases with missing data. Wait time and sensitization were not considered for inclusion in the final models, due to
excessive missing data.
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provide reassurance to the transplant community and to fu-
ture potential nondirected kidney donors.
Although in general, kidney donors have reported good
health related quality of life following donation,25 there are
risks inherent to this operation. Such risks highlight the need
for informed consent for living donors and include a small in-
crease in risk of developing to end-stage renal disease, gesta-
tional hypertension, and preeclampsia, as well as possible
financial loss.26,27
Given the excellent outcomes for NKD kidneys demon-
strated, efforts should focus on how best to use such organs.
From an organ utilization perspective, the use of NKD organs
to initiate transplant chains would seem ideal, with multiple
recipients benefitting from a single donated organ. Not only
does this increase the beneficiaries of transplantation, it also
facilitates the transplantation of patients whowould otherwise
have been difficult to find an immunologically compatible
organ. This could result in a decrease in need for blood
group/HLA incompatible transplantation with its associ-
ated morbidity and financial costs.28 Given that the use of
NKD kidneys to trigger donor chains would appear to satisfy
all ethical standpoints, it would seem reasonable to prioritize
NKD organs for these purposes.
Although the first report ofNKD transplantation was over
4 years ago,29 the practice has only recently become common-
place, with the vast majority of NKD transplants in the United
Kingdom performed after 2010. As a result, long term out-
come data is not available in this cohort and is a weakness
of this study. Although NKD is relatively commonplace in
the United Kingdom, compared with many countries, the ab-
solute number of NKD transplant is still relatively small and
therefore this study may lack power to detect subtle outcome
differences between NKD and SKD cohorts. Although we
considered a wide range of factors in this dual data set anal-
ysis, this was not exhaustive as some variables, such as recip-
ient BMI, smoking status and surgical technique of donor
nephrectomy were not available.
Nevertheless, in this national cohort study, we detail the ex-
cellent outcomes for NKD kidneys in the United Kingdom.
These results are reassuring, given that they are contribut-
ing an increasingly significant portion of live donor trans-
plants performed.
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